The efficacy of ivabradine use in case of chronic cardiac insufficiency


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Article highlites new perspectives of chronic cardiac insufficiency treatmet connected with sinoatrial node f-channels blocker ivabradine use that was fixed during the last years. The results of such large multicenter randomized trials as BEAUTIFUL, SHIFT and others are introduced. The efficacy of ivabradine use in case of chronic cardiac insufficiency with decreased systolic function is convincingly proved there. A special attention is paid to clinical situations, when ivabradine administration is rational in combination with β- adrenoblockers or without them in case of contraindications. The advantages of ivabradine prescribtion in case of combination chronic cardiac insufficiency with obstructive pulmonary disease, diabetes melitus, chronic renal pathology and other comorbid conditions are shown.

全文:

受限制的访问

作者简介

Igor Shaposhnik

South Ural State medical university

Email: shaposhnik@yandex.ru
MD, professor, Head of the Department of propaedeutics of internal diseases

参考

  1. Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности 2016. Российский кардиологический журнал.2017;1:7-81. [ESC guidelines on the diagnosis and treatment of acute and chronic heart failure 2016. Russian journal of cardiology. 2017;1:7-81 (in Russ.)]
  2. Yancy C., Jessup M., Bozkurt B. et al. 2016 ACC/AHA/HESA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation. 2017;4:14-32.
  3. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (4-й пересмотр). Сердечная недостаточность. 2013;7:379-472. [National recommendations of OSSN, RKO and RNMOT for diagnostics and treatment of chronic cardiac insufficiency (4th review)]
  4. Бойцов С.А., Зайратьянц О.В., Андреев Е.М., Самородская И.В. Сравнение показателей смертности от ишемической болезни сердца среди мужчин и женщин старше 50 лет в России и США. Российский кардиологический журнал. 2017;6:100-7. [Boytzov S.A., Zayratjanz O.V., Andreev E.M., Samorodskaya I.V. Comparison of cardiac ischemic disease mortality idexes among males and females older than 50 y.o. in Russia and USA. Russian cardiological journal. 2017;6:100-7]
  5. Терещенко С.Н., Жиров И.В., Кочетов А.В., Успенская О.В. «Новые» классы препаратов в лечении хронической сердечной недостаточности и их доказательная база. Рациональная фармакотерапия в кардиологии. 2012;8[2]:211 -16. [Tereshenko S.N., Zhirov I.V., Kochetov A.V., Uspenskaya O.V. «New» classes of medicines in chronic cardiac insufficiency treatment and their evidentary basis. Rational pharmacotherapy in cardiology. 2012;8(2):211-16.]
  6. Gheorghiade M., Patel K., Filippatos G., Anker S.D., van Veldhuisen D.J., Cleland J.G., Metra M., Aban I.B., Greene S.J., Adams K.F., McMurray J.J., Ahmed A. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur. J. Heart Fail. 2013;15(5):551-9.
  7. Шапошник И.И. Трудности применения ß-блокаторов при хронической сердечной недостаточности: пути преодоления. Русский медицинский журнал.2015;27:1617-21. [Shaposhnik I.I. Difficulties of ß-blockers use in case of chronic cardiac insufficiency: ways of overcoming. Russian medical journal. 2015;27:1617-21.]
  8. De Ferrari G., Mazzuero A., Agnesina L., Bertoletti A., Lettino M., Campana C., Schwartz P.J., Tavazzi L. Favorable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur. J. Hear Fail. 2008;10:550-5.
  9. Fox K., Ford I., Steg P., Tendera M., Robertson M., Ferrari R.; BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction. Lancet. 2008;372:817-21.
  10. Swedberg K., Komajda M., Bohm M., Borer J.S., Ford I., Dubost-Brama A., Lerebours G., Tavazzi L.; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet. 2010;376: 875-85.
  11. Borer J., Bohm M., Ford I., Komajda M., Tavazzi L., Sendon J.L., Alings M., Lopez-de-Sa E., Swedberg K.; SHIFT Investigators. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients chronic systolic heart failure: the SHIFT Study. Eur. Heart J. 2012;33(22):2813-20.
  12. Swedberg K., Komajda M., Bohm M., Borer J., Robertson M., Tavazzi L., Ford I.; SHIFT Investigators. Effects on outcomes of heart rate reduction by ivabradine in patients with the congestive heart failure: Study findings from the SHIFT. J. Am. Coll. Cardiol. 2012;59:1938-45.
  13. Zugck C., Martinka P., Stockl G. Ивабрадин в лечении пациентов с хронической сердечной недостаточностью: уменьшение симптомов и улучшение качества жизни в реальной клинической практике. Серцева недостатшсть.2015;1:28-39.
  14. Zugck C., Martinka P., Stockl G. Ivabradine in treatment of chronic cardiac insufficiency patients: reduce of symptoms and improvement of life quality in real clinical practice.201;1:28-39.
  15. Koester R., Kaehler J., Ebelt H. Ivabradine in combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice. Cllin. Res. Cardiol. 2010;99:665-72.
  16. Hidalgo F., Anguita M., Castillo J., Rodriguez S., Pardo L., Duran E., Sanchez J.J., Ferreiro C., Pan M., Mesa D., Delgado M., Ruiz M. Effect of early treatment with ivabradine in combination with ß-blockers compared with treatment by β-blockers in patients hospitalized with heart failure and reduced ejection fraction of the left ventricle. Int. J. Cardiol. 2016;217:7-11

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2017
##common.cookie##